Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.

Researchers in from Nanjing Drum Tower Hospital have presented data from a study that investigated the role of immunoglobulin superfamily member 6 (IGSF6) microglia during ischemic stroke.

Med-tech companies secured $2.76 billion across financings 56 transactions in January 2025, up from $1.72 billion in December ...

The fast pace in which the Trump administration has rolled out changes to how government and businesses operate – a ...

The U.K.’s National Institute for Health and Care Excellence (NICE) historically relies on cost savings to vet novel medical ...

Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody ...

Adrenomedullin, a hormone first identified in an adrenal medullary tumor, disrupts the effect of insulin on the endothelium of blood vessels, leading to insulin resistance linked to obesity and type 2 ...

For the pharmaceutical industry caught in the crosshairs of a potential trade war, the consequences of U.S. tariffs on China ...

Cognition Therapeutics Inc. evolved from the work of a neuroscientist and a chemist working in the San Francisco Bay area, seeking out targets to block the effects of Alzheimer’s disease. Since the ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...